Is Entyvio Approved for Crohn's Disease?
Yes, Entyvio (vedolizumab) is FDA-approved to treat adults with moderately to severely active Crohn's disease. It works by blocking integrin receptors on white blood cells, preventing them from entering the gut and causing inflammation. Approval came in 2014 for ulcerative colitis and expanded to Crohn's in 2016 after clinical trials showed it induced and maintained remission in patients who failed other therapies.[1][2]
How Does Entyvio Work for Crohn's?
Entyvio targets alpha4beta7 integrin, a protein that helps immune cells migrate to the gut lining. By binding to it, the drug keeps these cells out of inflamed areas, reducing Crohn's symptoms like abdominal pain, diarrhea, and weight loss. It's given as an IV infusion every 8 weeks after initial doses, with a gut-specific action that limits systemic side effects compared to broader immunosuppressants.[1]
Clinical Trial Results for Crohn's
In the GEMINI 2 and 3 trials, about 15-20% of Crohn's patients achieved clinical remission at week 6 with Entyvio, versus 7-12% on placebo. Long-term data showed sustained response in over 40% at one year. It's most effective for patients with inflammation limited to the gut, not those with fistulas or strictures.[2][3]
Who Qualifies for Entyvio in Crohn's?
Physicians prescribe it for moderate-to-severe cases unresponsive to conventional therapy (steroids, immunomodulators) or TNF inhibitors like Humira. It's not first-line and requires screening for infections like tuberculosis before starting.[1]
Common Side Effects and Risks
Patients report upper respiratory infections (13%), joint pain (12%), and nausea (11%). Serious risks include infusion reactions, progressive multifocal leukoencephalopathy (rare brain infection), and increased infection risk. Long-term use shows low malignancy rates, but monitoring is needed.[1][2]
How Does It Compare to Other Crohn's Treatments?
| Treatment | Mechanism | Dosing | Remission Rate (Induction) | Key Differences |
|-----------|-----------|--------|----------------------------|-----------------|
| Entyvio | Gut-selective integrin blocker | IV every 8 weeks | 15-20% | Lower infection risk outside gut |
| Humira (adalimumab) | TNF-alpha inhibitor | SubQ every 2 weeks | 20-30% | Broader systemic effects, higher infection risk |
| Stelara (ustekinumab) | IL-12/23 inhibitor | IV then SubQ | 20-25% | Works on different cytokines, subcutaneous option |
| Janssen's Tremfya (guselkumab) | IL-23 inhibitor | SubQ | Emerging data ~25% | Newer, targets single cytokine |
Entyvio shines for TNF-failures but may underperform in fibrostenotic Crohn's.[3][4]
Cost and Access for Crohn's Patients
A year's treatment costs $70,000-$80,000 without insurance. Patient assistance programs from Takeda (manufacturer) cover copays for eligible U.S. patients. Biosimilars are not yet available; patents extend into the 2030s.[5]
When Does Entyvio's Patent Expire?
Key U.S. patents on vedolizumab expire around 2027-2031, with formulation patents to 2033. No approved biosimilars yet, though challenges are ongoing. Check DrugPatentWatch.com for updates on litigation and expiry dates.[5]
[1]: Entyvio Prescribing Information, FDA (2023). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761157s000lbl.pdf
[2]: Sandborn et al., NEJM (2013). GEMINI 2 Trial. https://www.nejm.org/doi/full/10.1056/NEJMoa1215739
[3]: ClinicalTrials.gov, NCT00783692 (GEMINI 3). https://clinicaltrials.gov/study/NCT00783692
[4]: Crohn's & Colitis Foundation Treatment Guidelines (2023). https://www.crohnscolitisfoundation.org/science-and-professionals/treatment
[5]: DrugPatentWatch.com, Vedolizumab Patents. https://www.drugpatentwatch.com/p/tradename/ENTYVIO